StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-18 | $9.11 | $8.37 | -8.18% | 1.0M |
| 05-19 | $8.19 | $8.40 | +2.63% | 0.9M |
| 05-20 | $8.52 | $8.47 | -0.59% | 0.5M |
| 05-21 | $8.29 | $8.69 | +4.83% | 0.6M |
| 05-22 | $8.68 | $8.60 | -0.92% | 0.5M |
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
No sell-side coverage available for FDMT yet.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
4D Molecular Therapeutics Inc is biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Companies focus is on advancing 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) through late-stage studies. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector).
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $3.05M | $85.21M | $119.00K | $29.00K |
Operating Income | $-73.62M | $-159.55M | $-174.26M | $-113.08M |
Net Income | $-68.76M | $-140.11M | $-159.51M | $-54.66M |
EPS (Diluted) | $-1.01 | $-2.42 | $-2.85 | $-1.84 |
Total Assets | $512.90M | $566.71M | $423.98M | $473.64M |
Total Liabilities | $61.07M | $61.05M | $55.00M | $52.75M |
Cash & Equivalents | $72.49M | $60.24M | $48.55M | $77.16M |
Free Cash Flow OCF − CapEx | Not available | $-109.62M | $-138.24M | $-91.83M |
Shares Outstanding | 52.27M | 57.61M | 46.77M | 46.70M |